aTyr Pharma Inc (ATYR) is not a strong buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock lacks significant positive catalysts, has weak financial performance, and no strong technical or proprietary trading signals to support an immediate buy decision. Holding or exploring other opportunities is recommended.

Technical Analysis

The MACD is slightly positive but contracting, RSI is neutral at 53.991, and moving averages are converging, indicating no clear trend. Key support and resistance levels are at 0.884 and 1.081, respectively, with the current price near the pivot at 0.983. Overall, the technical indicators suggest a neutral trend.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

The low put-call ratios indicate a lack of bearish sentiment, but the low volume and open interest suggest limited market activity and interest in the stock.

Technical Summary

Sell

Buy

Positive Catalysts

NULL identified. No recent news or significant events to act as a positive catalyst.

Neutral/Negative Catalysts

The stock has shown a regular market decline of -2.94% and a post-market decline of -0.60%. Financial performance remains weak with negative net income and EPS, despite some YoY improvement.

Financial Performance

In Q3 2025, revenue remained flat YoY at $190,000. Net income improved YoY but is still negative at -$25.74M. EPS improved to -0.26 (up 13.04% YoY), and gross margin remained at 100%. Overall, the company is not profitable and shows limited growth.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data available for trend analysis or analyst ratings. Wall Street sentiment is unclear.

2 Analyst Rating

Wall Street analysts forecast ATYR stock price to rise

0 Buy

2 Hold

0 Sell

Hold

Current: 0.960

Low

Averages

High

Current: 0.960

Low

Averages

High

Leerink

Faisal Khurshid

Outperform

maintain

$NULL

AI Analysis

2025-09-15

Reason

Leerink

Faisal Khurshid

Price Target

$NULL

AI Analysis

2025-09-15

maintain

Outperform

Reason

Leerink analyst Faisal Khurshid keeps an Outperform rating on aTyr Pharma after the company said the Phase 3 EFZO-FIT trial of efzofitimod in pulmonary sarcoidosis failed to meet its primary endpoint of steroid reduction. While aTyr plans to engage with the FDA on a potential path forward, Leerink's expectations are low given the primary endpoint miss and unclear relevance of KSQ-Lung score improvements alone, the analyst tells investors in a research note. Going into the readout, the firm expected a primary endpoint miss would see 80%-90% share downside. aTyr Pharma shares are down 82%, or $4.97, to $1.07 in early trading.

Cantor Fitzgerald

Overweight -> Neutral

downgrade

2025-09-15

Reason

Cantor Fitzgerald

Price Target

2025-09-15

downgrade

Overweight -> Neutral

Reason

Cantor Fitzgerald downgraded aTyr Pharma to Neutral from Overweight after the company announced that the Phase 3 pulmonary sarcoidosis trial for efzofitimod missed the primary endpoint of change in mean steroid dose from baseline at week 48. aTyr plans to engage with the FDA to determine the path forward, but the firm doesn't have much confidence in the path forward for efzo in pulmonary sarcoidosis, the analyst tells investors.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ATYR

Unlock Now

ATYR Should I Buy

ATYR Should I Buy

Should You Buy aTyr Pharma Inc (ATYR) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch